A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas

Federica Mori, Patrizia Giannetti, Daniela Peruzzi, Domenico Lazzaro, Saverio Giampaoli, Howard L. Kaufman, Gennaro Ciliberto, Nicola La Monica, Luigi Aurisicchio

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A genetic vaccine platform based on DNA electroporation (DNA-EP) and adenovirus (Ad) was used to generate immune response against human carcinoembryonic antigen (CEA) and antitumor effects in murine models with spontaneous tumors arising in an orthotopic location. CEA transgenic (CEA.Tg) mice treated with the carcinogen 1,2-dimethylhydrazine developed CEA-overexpressing tumors that resembled human sporadic colorectal cancer. APC1638N/CEA hybrid mice, generated by crossing mice carrying the adenomatous polyposis coli (Apc1638N) gene mutation with CEA.Tg mice, are representative of human familial polyposis and develop polyps that overexpress the antigen. In both models, the DNA-EP/Ad vaccine succeeded in breaking immune tolerance and achieved significant antitumor effects in therapeutic settings. Our data suggest that genetic vaccines targeting CEA may be feasible strategies against gut tumors that overexpress the antigen. In addition, these models are powerful systems for evaluating antigen-specific tumor immunity and assessing therapeutic vaccine strategies for human colorectal cancer.

Original languageEnglish
Pages (from-to)125-136
Number of pages12
JournalHuman Gene Therapy
Volume20
Issue number2
DOIs
Publication statusPublished - Feb 1 2009

Fingerprint

Cancer Vaccines
Carcinoembryonic Antigen
Carcinoma
Electroporation
Vaccines
Neoplasm Antigens
Colorectal Neoplasms
Adenovirus Vaccines
Therapeutics
1,2-Dimethylhydrazine
APC Genes
Immune Tolerance
DNA
Therapeutic Uses
Polyps
Adenoviridae
Carcinogens
Transgenic Mice
Immunity
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Mori, F., Giannetti, P., Peruzzi, D., Lazzaro, D., Giampaoli, S., Kaufman, H. L., ... Aurisicchio, L. (2009). A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Human Gene Therapy, 20(2), 125-136. https://doi.org/10.1089/hum.2008.116

A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. / Mori, Federica; Giannetti, Patrizia; Peruzzi, Daniela; Lazzaro, Domenico; Giampaoli, Saverio; Kaufman, Howard L.; Ciliberto, Gennaro; La Monica, Nicola; Aurisicchio, Luigi.

In: Human Gene Therapy, Vol. 20, No. 2, 01.02.2009, p. 125-136.

Research output: Contribution to journalArticle

Mori, F, Giannetti, P, Peruzzi, D, Lazzaro, D, Giampaoli, S, Kaufman, HL, Ciliberto, G, La Monica, N & Aurisicchio, L 2009, 'A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas', Human Gene Therapy, vol. 20, no. 2, pp. 125-136. https://doi.org/10.1089/hum.2008.116
Mori F, Giannetti P, Peruzzi D, Lazzaro D, Giampaoli S, Kaufman HL et al. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Human Gene Therapy. 2009 Feb 1;20(2):125-136. https://doi.org/10.1089/hum.2008.116
Mori, Federica ; Giannetti, Patrizia ; Peruzzi, Daniela ; Lazzaro, Domenico ; Giampaoli, Saverio ; Kaufman, Howard L. ; Ciliberto, Gennaro ; La Monica, Nicola ; Aurisicchio, Luigi. / A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. In: Human Gene Therapy. 2009 ; Vol. 20, No. 2. pp. 125-136.
@article{54c9373af7794205b4d60029a75cd801,
title = "A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas",
abstract = "A genetic vaccine platform based on DNA electroporation (DNA-EP) and adenovirus (Ad) was used to generate immune response against human carcinoembryonic antigen (CEA) and antitumor effects in murine models with spontaneous tumors arising in an orthotopic location. CEA transgenic (CEA.Tg) mice treated with the carcinogen 1,2-dimethylhydrazine developed CEA-overexpressing tumors that resembled human sporadic colorectal cancer. APC1638N/CEA hybrid mice, generated by crossing mice carrying the adenomatous polyposis coli (Apc1638N) gene mutation with CEA.Tg mice, are representative of human familial polyposis and develop polyps that overexpress the antigen. In both models, the DNA-EP/Ad vaccine succeeded in breaking immune tolerance and achieved significant antitumor effects in therapeutic settings. Our data suggest that genetic vaccines targeting CEA may be feasible strategies against gut tumors that overexpress the antigen. In addition, these models are powerful systems for evaluating antigen-specific tumor immunity and assessing therapeutic vaccine strategies for human colorectal cancer.",
author = "Federica Mori and Patrizia Giannetti and Daniela Peruzzi and Domenico Lazzaro and Saverio Giampaoli and Kaufman, {Howard L.} and Gennaro Ciliberto and {La Monica}, Nicola and Luigi Aurisicchio",
year = "2009",
month = "2",
day = "1",
doi = "10.1089/hum.2008.116",
language = "English",
volume = "20",
pages = "125--136",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas

AU - Mori, Federica

AU - Giannetti, Patrizia

AU - Peruzzi, Daniela

AU - Lazzaro, Domenico

AU - Giampaoli, Saverio

AU - Kaufman, Howard L.

AU - Ciliberto, Gennaro

AU - La Monica, Nicola

AU - Aurisicchio, Luigi

PY - 2009/2/1

Y1 - 2009/2/1

N2 - A genetic vaccine platform based on DNA electroporation (DNA-EP) and adenovirus (Ad) was used to generate immune response against human carcinoembryonic antigen (CEA) and antitumor effects in murine models with spontaneous tumors arising in an orthotopic location. CEA transgenic (CEA.Tg) mice treated with the carcinogen 1,2-dimethylhydrazine developed CEA-overexpressing tumors that resembled human sporadic colorectal cancer. APC1638N/CEA hybrid mice, generated by crossing mice carrying the adenomatous polyposis coli (Apc1638N) gene mutation with CEA.Tg mice, are representative of human familial polyposis and develop polyps that overexpress the antigen. In both models, the DNA-EP/Ad vaccine succeeded in breaking immune tolerance and achieved significant antitumor effects in therapeutic settings. Our data suggest that genetic vaccines targeting CEA may be feasible strategies against gut tumors that overexpress the antigen. In addition, these models are powerful systems for evaluating antigen-specific tumor immunity and assessing therapeutic vaccine strategies for human colorectal cancer.

AB - A genetic vaccine platform based on DNA electroporation (DNA-EP) and adenovirus (Ad) was used to generate immune response against human carcinoembryonic antigen (CEA) and antitumor effects in murine models with spontaneous tumors arising in an orthotopic location. CEA transgenic (CEA.Tg) mice treated with the carcinogen 1,2-dimethylhydrazine developed CEA-overexpressing tumors that resembled human sporadic colorectal cancer. APC1638N/CEA hybrid mice, generated by crossing mice carrying the adenomatous polyposis coli (Apc1638N) gene mutation with CEA.Tg mice, are representative of human familial polyposis and develop polyps that overexpress the antigen. In both models, the DNA-EP/Ad vaccine succeeded in breaking immune tolerance and achieved significant antitumor effects in therapeutic settings. Our data suggest that genetic vaccines targeting CEA may be feasible strategies against gut tumors that overexpress the antigen. In addition, these models are powerful systems for evaluating antigen-specific tumor immunity and assessing therapeutic vaccine strategies for human colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=58849156873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849156873&partnerID=8YFLogxK

U2 - 10.1089/hum.2008.116

DO - 10.1089/hum.2008.116

M3 - Article

VL - 20

SP - 125

EP - 136

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -